GoodRx Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by GoodRx Holdings, Inc. on June 3, 2025. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation advisory votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Approximately 99.5% of the combined voting power was present at the meeting. The following proposals were approved:
- Director Elections (Item 1): Christopher Adams, Trevor Bezdek, and Scott Wagner were elected as Class II directors for a term expiring in 2028. Each director received over 2.6 billion votes in favor.
- Auditor Ratification (Item 2): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation (Item 3): Stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the final voting percentages for the three Class II director nominees to assess shareholder support levels.
- Confirm the appointment of PricewaterhouseCoopers LLP for the 2025 fiscal year in subsequent filings.
- Review the Definitive Proxy Statement filed on April 23, 2025, for detailed context on the executive compensation proposal.
- Check the record date of April 9, 2025, to confirm eligibility for the voting shares.